Arbutus Biopharma Corporation (ABUS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.3100 |
| Open | 2.3200 |
| Bid | 2.4600 x 3100 |
| Ask | 2.5000 x 3200 |
| Day's Range | 2.2650 - 2.5000 |
| 52 Week Range | 1.9300 - 6.5000 |
| Volume | |
| Avg. Volume | 1,533,293 |
| Market Cap | 368.845M |
| Beta (5Y Monthly) | 2.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7050 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.70 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ABUS
Related Research
- Arbutus Biopharma CorporationAnalyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.RatingFair ValueEconomic Moat2 days agoMorningstar
- GlobeNewswire
Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a preclinical oncology study for one of Arbutus’ oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual
- Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual MeetingGlobeNewswire
- Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual MeetingBusiness Wire
- American City Business Journals
Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds
The Pennsylvania Biotechnology Center of Bucks County and its affiliated organizations have generated an economic impact of $7.3 billion for the state during the past six years, according to a new study. The analysis, conducted by KLIOS Consulting economist Richard M. Stein, found that between the beginning of 2016 and the end of 2021, the biotech center produced a $2.3 billion direct impact tied to spending and economic activity at the center, and another $3.5 billion in indirect spending elsewhere in Pennsylvania tied to initial economic activity at the center. The remaining $1.5 billion represents the center's "induced impact," which is economic benefit related to additional household spending created from biotech center activities and related indirect economic activity.
- GlobeNewswire
Arbutus to Present at H.C. Wainwright Global Investment Conference
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL. A live webcast of the presentation can be ac
